NEW YORK (GenomeWeb) – Biodesix today announced that Health Net has issued a positive coverage decision for the VeriStrat test.
According to Biodesix, Health Net considers the test medically necessary for patients with advanced non-small cell lung cancer and wild-type EGFR or with unknown EGFR status. Health Net covers about 5.9 million lives, primarily on the US West Coast.
Last month Biodesix said that Aetna and Cigna began covering VeriStrat, a MALDI mass spec-based test that identifies patients likely to respond to treatment with EGFR inhibitors.